About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
https://www.weizmann-usa.org/news-media/news-releases/science-tips-february-2011/
Feb 10, 2011...
Two new studies support a novel approach based on Weizmann Institute scientists’ research
Much of the devastation of stroke and head trauma is due to damage caused by the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don’t cross the blood-brain barrier, and those that do often don’t work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.
https://www.weizmann-usa.org/news-media/news-releases/science-tips-august-2014/
Aug 11, 2014... Blood stem cells have the potential to turn into any type of blood cell, whether it be the oxygen-carrying red blood cells, or the immune system’s many types of white blood cells that help fight infection. How exactly is the fate of these stem cells regulated? Preliminary findings from research conducted by scientists from the Weizmann Institute of Science and the Hebrew University are starting to reshape the conventional understanding of the way blood stem cell fate decisions are controlled, thanks to a new technique for epigenetic analysis they have developed. Understanding epigenetic mechanisms (environmental influences other than genetics) of cell fate could lead to the deciphering of the molecular mechanisms of many diseases, including immunological disorders, anemia, leukemia, and many more. It also lends strong support to findings that environmental factors and lifestyle play a more prominent role in shaping our destiny than previously realized.
Jul 15, 2013...
Scientists have found that very high levels of stress in the mother can also overwhelm the barrier enzyme in the placenta, allowing the stress hormone cortisol to cross into the foetus’s brain. Photo: PA
Researchers have discovered a key component of the placenta that normally protects unborn babies from high levels of hormones that build up in their mothers’ blood when she is stressed.
In some mothers, however, this protective element can be faulty, allowing the foetus to be exposed to stress hormones and leaving a child more prone to anxiety and depression in later life.
Jan 02, 2019...
Tumor heterogeneity, clonal evolution and therapy resistance revealed using single-cell profiling of multiple myeloma patients. Illustration by Noa Godin/Weizmann Institute of Science
Israeli researchers have developed a new technology that profiles the genetic makeup of cancerous cells, allowing for better diagnosis and treatment.
Multiple myeloma is the second most-common type of blood cancer. Multiple myeloma occurs when plasma cells in the bone marrow – the cells that produce antibodies – proliferate out of control and lead to organ failure and death.
Dec 14, 2018...
In this work, the team studies vascular networks formed by a coculture of fibroblasts and endothelial cells embedded in three-dimensional biomaterials experiencing external, physiologically relevant forces. (© ACS)
Israeli scientists from the Technion-Israel Institute of Technology and the Weizmann Institute of Science recently combined one group’s expertise in tissue engineering with the other’s expertise in the physics of complex systems to understand in detail how mechanical forces can direct the orientation of developing blood vessels.
Dec 22, 2013...
In our recent “Top 12 most amazing Israeli medical advances”, we promised a top 10 list of the most exciting Israeli medical-device and pharmaceutical developments just around the corner.
Like the top 12, this list was also very difficult to narrow down, because Israeli breakthroughs in this field are a near-daily occurrence. Our top 10 is just the tip of the iceberg.
Watch for new health stories on ISRAEL21c every week for a broader picture of how Israeli ingenuity is changing the face of healthcare worldwide.
Nov 11, 2015... NEW YORK, NY — (Marketwired - November 11, 2015) – Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today initial indications that its Megadose Drug Combination has been used to successfully treat a cancer patient in Italy. Cell Source's proprietary Megadose Drug Combination (licensed exclusively from the Weizmann Institute of Science in Israel) is expected to increase bone marrow transplantation (BMT) success and survival.
Apr 27, 2020... On May 2, 1986, while visiting my long-term colleague and friend Richard O’Reilly, the head of bone marrow transplantation at Memorial Sloan Kettering Cancer Center in New York, I received a strange phone call. It was from Richard Champlin, who worked at the Bone Marrow Transplant Center at UCLA. He tended to speak very fast, so it took me some time to understand from his over-excited voice that he was about to leave the next day for Moscow.
Sep 04, 2020...
Blood cancers are far too common, comprising almost 10% of new cancer diagnoses each year in the U.S. Almost every 10 minutes, an American succumbs to a blood cancer. Unfortunately, many of these are children.
That's why the Weizmann Institute of Science’s researchers are conducting innovative studies and taking novel approaches to blood cancers. September is Blood Cancer Awareness Month, and we’d like to share with you some of Weizmann’s current investigations.
Jan 19, 2021... Prof. Karina Yaniv, Department of Biological Regulation, explains why it is so important to understand embryonic development. Across life forms, development is similar; in fact, it can be hard to distinguish between embryos from different species...
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
